Want to see SEPN full AI Analyst Report?
SEPN Stock Chart & Stats
$26.13
$0.38(1.86%)
At close: 4:00 PM EST
$26.13
$0.38(1.86%)
Day’s Range― - ―
52-Week Range$10.30 - $37.99
Previous CloseN/A
Volume49.14K
Average Volume (3M)320.59K
Market Cap
$1.68B
Enterprise Value$1.57B
Total Cash (Recent Filing)$347.40M
Total Debt (Recent Filing)$23.09M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Aug 17, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding45,075,535
10 Day Avg. Volume315,821
30 Day Avg. Volume320,586
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.23
Price to Sales (P/S)26.85
P/FCF Ratio11.25
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue21.66
Enterprise Value/Gross Profit21.79
Enterprise Value/Ebitda-30.03
Forecast
1Y Price Target
$49.33Price Target Upside88.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.65
Revenue Forecast (FY)$76.95M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained, sharp revenue growth across 2025 and TTM 2026 indicates improving commercial traction or successful monetization of programs. Over the next 2–6 months this momentum supports scaling, reduces near-term funding reliance, and strengthens bargaining power with partners and suppliers.
Improved Cash GenerationTransition to robust operating and free cash flow materially lowers financing risk and gives management optionality to fund R&D, operations, or partnerships without immediate dilution. Positive cash generation is a durable buffer that supports execution over several quarters.
Phase 1 Trial ProgressInitiation of a randomized, placebo-controlled Phase 1 for SEP-479 is a structural pipeline advancement. Clinical progress de-risks the program if data are favorable, strengthens the company’s scientific credibility, and can enable partnerships or licensing over the medium term.
Bears Say
Negative Operating MarginsPersistent sizable operating losses mean the business is not yet self-sustaining from operations. Even with revenue growth, ongoing negative margins will require sustained cash or external financing, constraining capital allocation and limiting long-term profitability until costs scale or revenues increase further.
Negative Return On EquityNegative ROE over multiple periods shows shareholders' capital has not generated positive economic returns, signaling underlying profitability issues. That structural weakness can pressure investor support and make internal funding for growth less viable absent improved margins or profitable assets.
Clinical Milestone ConcentrationThe company’s near- to mid-term value materially depends on SEP-479 Phase 1 readouts. Clinical outcomes or delays are binary and can materially alter strategic options, funding access, and partner interest, creating concentrated program risk over the next several quarters.
Septerna, Inc. News
SEPN FAQ
What was Septerna, Inc.’s price range in the past 12 months?
Septerna, Inc. lowest stock price was $10.30 and its highest was $37.99 in the past 12 months.
What is Septerna, Inc.’s market cap?
Septerna, Inc.’s market cap is $1.68B.
When is Septerna, Inc.’s upcoming earnings report date?
Septerna, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 47 days.
How were Septerna, Inc.’s earnings last quarter?
Septerna, Inc. released its earnings results on May 11, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.227.
Is Septerna, Inc. overvalued?
According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued.
Does Septerna, Inc. pay dividends?
Septerna, Inc. does not currently pay dividends.
What is Septerna, Inc.’s EPS estimate?
Septerna, Inc.’s EPS estimate is -0.43.
How many shares outstanding does Septerna, Inc. have?
Septerna, Inc. has 45,075,535 shares outstanding.
What happened to Septerna, Inc.’s price movement after its last earnings report?
Septerna, Inc. reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went up 5.388%.
Which hedge fund is a major shareholder of Septerna, Inc.?
Currently, no hedge funds are holding shares in SEPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Septerna, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.33 (88.80% Upside)
$49.33 (88.80% Upside)
Blogger Sentiment
Bullish
SEPN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 620.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 21.0%
Last 30 Days ▲ 21.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
230.63%
12-Months-Change
Fundamentals
Return on Equity
-9.44%
Trailing 12-Months
Asset Growth
31.26%
Trailing 12-Months
Company Description
Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
SEPN Stock 12 Month Forecast
Average Price Target
$49.33
▲(88.80% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
―
Ownership Overview
2.81% Insiders
8.76% Mutual Funds
77.57% Other Institutional Investors
4.12% Public Companies and
Individual Investors